NeuroSense Therapeutics (NeuroSense Therapeutics) 3-Year EBITDA Growth Rate : -47.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics 3-Year EBITDA Growth Rate?

NeuroSense Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was $0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was -47.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of NeuroSense Therapeutics was -47.00% per year. The lowest was -111.20% per year. And the median was -79.10% per year.

Competitive Comparison of NeuroSense Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, NeuroSense Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's 3-Year EBITDA Growth Rate falls into.

NeuroSense Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

NeuroSense Therapeutics (NAS:NRSNW) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

NeuroSense Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSNW) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

NRSN:USA

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4676670

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.